Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins.

Yoshimi A, Goyama S, Watanabe-Okochi N, Yoshiki Y, Nannya Y, Nitta E, Arai S, Sato T, Shimabe M, Nakagawa M, Imai Y, Kitamura T, Kurokawa M.

Blood. 2011 Mar 31;117(13):3617-28. doi: 10.1182/blood-2009-12-261602. Epub 2011 Feb 2.

2.

Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1.

Lugthart S, Figueroa ME, Bindels E, Skrabanek L, Valk PJ, Li Y, Meyer S, Erpelinck-Verschueren C, Greally J, Löwenberg B, Melnick A, Delwel R.

Blood. 2011 Jan 6;117(1):234-41. doi: 10.1182/blood-2010-04-281337. Epub 2010 Sep 20.

3.

Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia.

Kornblau SM, McCue D, Singh N, Chen W, Estrov Z, Coombes KR.

Blood. 2010 Nov 18;116(20):4251-61. doi: 10.1182/blood-2010-01-262071. Epub 2010 Aug 2.

4.

Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.

Lugthart S, Gröschel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL, Jan Ossenkoppele G, Vellenga E, van den Berg-de Ruiter E, Schanz U, Verhoef G, Vandenberghe P, Ferrant A, Köhne CH, Pfreundschuh M, Horst HA, Koller E, von Lilienfeld-Toal M, Bentz M, Ganser A, Schlegelberger B, Jotterand M, Krauter J, Pabst T, Theobald M, Schlenk RF, Delwel R, Döhner K, Löwenberg B, Döhner H.

J Clin Oncol. 2010 Aug 20;28(24):3890-8. doi: 10.1200/JCO.2010.29.2771. Epub 2010 Jul 26.

PMID:
20660833
5.

Darinaparsin: a novel organic arsenical with promising anticancer activity.

Mann KK, Wallner B, Lossos IS, Miller WH Jr.

Expert Opin Investig Drugs. 2009 Nov;18(11):1727-34. doi: 10.1517/13543780903282759. Review.

PMID:
19780704
6.

A phase I clinical trial of darinaparsin in patients with refractory solid tumors.

Tsimberidou AM, Camacho LH, Verstovsek S, Ng C, Hong DS, Uehara CK, Gutierrez C, Daring S, Stevens J, Komarnitsky PB, Schwartz B, Kurzrock R.

Clin Cancer Res. 2009 Jul 15;15(14):4769-76. doi: 10.1158/1078-0432.CCR-08-2984. Epub 2009 Jul 7.

7.

Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line.

Matulis SM, Morales AA, Yehiayan L, Croutch C, Gutman D, Cai Y, Lee KP, Boise LH.

Mol Cancer Ther. 2009 May;8(5):1197-206. doi: 10.1158/1535-7163.MCT-08-1072. Epub 2009 May 5.

8.

The interleukin-8 pathway in cancer.

Waugh DJ, Wilson C.

Clin Cancer Res. 2008 Nov 1;14(21):6735-41. doi: 10.1158/1078-0432.CCR-07-4843. Review.

9.

Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide.

Shackelford D, Kenific C, Blusztajn A, Waxman S, Ren R.

Cancer Res. 2006 Dec 1;66(23):11360-9.

10.

Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression.

Yuasa H, Oike Y, Iwama A, Nishikata I, Sugiyama D, Perkins A, Mucenski ML, Suda T, Morishita K.

EMBO J. 2005 Jun 1;24(11):1976-87. Epub 2005 May 12.

11.

Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression.

Raza A, Buonamici S, Lisak L, Tahir S, Li D, Imran M, Chaudary NI, Pervaiz H, Gallegos JA, Alvi MI, Mumtaz M, Gezer S, Venugopal P, Reddy P, Galili N, Candoni A, Singer J, Nucifora G.

Leuk Res. 2004 Aug;28(8):791-803.

PMID:
15203277
12.

The role of EVI1 in normal and leukemic cells.

Buonamici S, Chakraborty S, Senyuk V, Nucifora G.

Blood Cells Mol Dis. 2003 Sep-Oct;31(2):206-12. Review.

PMID:
12972028
13.

A simple fluorescence method for surface antigen phenotyping of lymphocytes undergoing DNA fragmentation.

Hardin JA, Sherr DH, DeMaria M, Lopez PA.

J Immunol Methods. 1992 Sep 18;154(1):99-107.

PMID:
1401949

Supplemental Content

Support Center